Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Management of multiple sclerosis: An overview.
Reduced axonal motor protein expression in non-lesional grey matter in multiple sclerosis.
Over six cups of coffee a day may reduce the risk of developing multiple sclerosis.
Acute disseminated encephalomyelitis in children: a single institution experience of 28 patients.
The role of mitochondria in axonal degeneration and tissue repair in MS.
Impact of diagnosis and early treatment on the course of multiple sclerosis.
TAPP1 inhibits the differentiation of oligodendrocyte precursor cells via suppressing the Mek/Erk pathway.
Effect of Multiple Infusions of AIN457 on Disease Activity in Relapsing-remitting Multiple Sclerosis
From injection therapies to natalizumab: views on the treatment of multiple sclerosis.
Is multiple sclerosis a proresolution deficiency disorder?
Potential role of OPG/RANKL system and FokI genotypes in pathogenesis and clinical manifestations in multiple sclerosis.
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development.
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
Successful treatment of psoriasis with ustekinumab in patients with multiple sclerosis.
RNF and Betaseron® Tolerability Study (REFORMS)
Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.
Neural stem/progenitor cells as a promising candidate for regenerative therapy of the central nervous system.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
The King-Devick (K-D) test of rapid eye movements: A bedside correlate of disability and quality of life in MS.
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.
Diffusion Tensor Imaging (DTI) - A New Imaging Technique Applyed in Multiple Sclerosis.
Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS.
Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial.
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica.
Pages
« first
‹ previous
…
177
178
179
180
181
182
183
184
185
…
next ›
last »